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To evaluate the contribution of antimicrobial use in human and veterinary medicine to
the emergence and spread of resistant bacteria, the use of these substances has to
be accurately monitored in each setting. Currently, various initiatives collect sales data
of veterinary antimicrobials, thereby providing an overview of quantities on the market.
However, sales data collected at the level of wholesalers or marketing authorization
holders are of limited use to associate with the prevalence of bacterial resistances at
species level. We converted sales data to the number of potential treatments of calves
and pigs in Switzerland for the years 2011 to 2015 using animal course doses (ACD).
For each authorized product, the number of potential therapies was derived from the
sales at wholesaler’s level and the ACD in mg per kg. For products registered for use in
multiple species, a percentage of the sales was attributed to each authorized species
according to their biomass distribution. We estimated a total of 5,914,349 therapies for
pigs and 1,407,450 for calves in 2015. Using the number of slaughtered animals for
that year as denominator, we calculated a treatment intensity of 2.15 therapies per pig
and 5.96 per calf. Between 2011 and 2015, sales of veterinary antimicrobials decreased
by 30%. The calculated number of potential therapies decreased by 30% for pigs and
15% for calves. An analysis of treatment intensity at antimicrobial class level showed
a decrease of 64% for colistin used in pigs, and of 7% for macrolides used in both
pigs and calves. Whereas the use of 3rd and 4th generation cephalosporins in calves
decreased by 15.8%, usage of fluoroquinolones increased by 10.8% in the same period.
Corresponding values for pigs were −16.4 and +0.7%. This is the first extrapolation
of antimicrobial usage at product level for pigs and calves in Switzerland. It shows that
calves were more frequently treated than pigs with a decreasing trend for both number
of therapies and use of colistin, macrolides and cephalosporins 3rd and 4th generations.
Nonetheless, we calculated an increase in the usage of fluoroquinolones. Altogether, this
study’s outcomes allow for trend analysis and can be used to assess the relationship
between antimicrobial use and resistance at the national level.
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INTRODUCTION
Use of antimicrobials contributes to the emergence and spread
of resistant bacteria in both humans and animals. As early as in
the 1960’s concerns arose in relation to therapeutic, preventive
and growth-promoting treatments in food-producing animals.
The fact that most antibiotic classes are administered to treat
infections in both humans and animals was one of the major
concerns (1, 2). Monitoring antimicrobial usage is therefore a
prerequisite to assess the impact of antibiotic treatments on
the selection and spread of bacterial resistances. In order to
achieve that goal, a number of programs monitoring sales and/or
usage of antimicrobials have been established both at national
level, for example in Switzerland [ARCH-Vet; (3)], Denmark
(4), and international level [ESVAC project of the European
Medicines Agency; (5)]. These programs do not only aim at the
identification of trends in sales and usage of antimicrobial classes
but should also allow establishing a link with changes observed
in resistance monitoring programs, thereby providing a basis
for risk assessment and evaluation of regulatory interventions
(6). In order to assess the association between antimicrobial use
and resistance, it is of crucial relevance to obtain consumption
data at species or, when possible, production type level; there
are several species and production type-specific factors that can
impact on the relationship between use and resistance. Those
factors include age at treatment, age and weight at slaughter,
products available per species or production type, and especially
production structures (7–9).
Antimicrobial sales data are defined as the minimal standard
for monitoring programs by the World Organization for Animal
Health [Office International des Epizooties, OIE; (10)]. They
can be collected at either the manufacturer, wholesaler or
pharmacy level depending on the national distribution routes
of the products. Sales data are useful to evaluate long-term
trends but do not include information about dose, route of
administration, indication or duration of therapy. However, in
the context of resistance epidemiology, only data about actual
use of antimicrobials collected either at prescription or patient
level might deliver the information necessary to establish and
evaluate implemented measures. Such data can only be currently
collected in few countries with advanced collection systems, such
as Denmark (4) and TheNetherlands (11) among other European
countries. The AACTING network is maintaining a list of the
various collection systems already in place (www.aacting.org).
The collection of data at animal level is the ultimate goal of
antimicrobial monitoring systems and, until this is available in all
participating countries, alternatives using normalization of sales
data by the total weight of the food producing animal population
as a denominator have been developed. One such denominator
is the population correction unit of the ESVAC project (12).
Other institutions (13) and countries, including Canada (14)
and Switzerland [ARCH-Vet; (3)], have implemented similar
methods in their surveillance systems. As usage of antimicrobials
is strongly dependent on population structure and repartition
between high and low-using species, the normalization by weight
may provide information on long-term trends but at the same
time, a higher usage in one species will be “diluted” by lower
usage species/production types (like dairy cows) with a large
contribution to the overall livestock biomass (15). It is therefore
important to measure antibiotic consumption as near as possible
to the end users, i.e., to obtain information on species, dosage,
duration and whenever possible, indication. The extrapolation
of sales data using course doses is an interim measure to data
collection at animal level. Course dose indicators have been
proposed, such as the Animal Course Dose (ACD) by the French
Agency for Food, Environmental, and Occupational Health &
Safety (16) or Defined Course Dose (DCDvet) from the EMA
(17). An advantage of ACD is its product-specific calculation,
therefore better representing national specificities than DCDvet
units. ACDs are established for each product using data from
the summary of product characteristics (SPC) and contain
the necessary detail on both dose and therefore potency, and
duration of use.
The main aim of this study was to provide for the first
time an extrapolation of the available national sales data to
the number of treated animals in Switzerland. We chose to
specifically investigate the treatment of pigs and calves because
these are mainly reared and treated in groups via oral application.
Due to the lack of detailed data about repartition of sales, we
made assumptions regarding weight at treatment and repartition
of sales data between species using a previously published
repartition method. We then defined ACD for each product
containing antimicrobials authorized in Switzerland for use in
either pigs or calves and combined this information with national
antibiotic sales data to extrapolate the number of potentially
treated animals during the years 2011 to 2015.
MATERIALS AND METHODS
Data Collection
Veterinary antibiotic sales data for the years 2011 to 2015
were obtained from the Federal Office of Food Safety under a
confidentiality agreement. Since 2004, sales data are collected
in Switzerland from marketing authorization holders based on
Article 35 of the Ordinance of Veterinary Medicines (18).
Marketing authorization holders are required to deliver data on
every product containing antimicrobials that was sold during
a calendar year. Products subject to data collection are defined
by their ATCvet codes (19) as listed in the ESVAC project
(12). Additionally, data on antibiotic products not considered
by the ESVAC project, like sprays or products to treat sensory
organs, are also collected. Data obtained from the Federal Office
of Food Safety for this study contained the quantity of active
antimicrobial ingredient sold in kilogram for each product and
year under investigation.
Animal Populations, Animal Weights, and
Species Repartition
The amount of antimicrobials sold of products authorized for a
single species was directly assigned to their target species. For
each product authorized for more than one species, a repartition
had to be determined. We used two distinct methods: the first
one was used for premixes, the latter being legally defined in
Switzerland as being “veterinary medicinal products used to treat
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groups of animals and incorporated into either water or feed”
[Ordinance on authorizations for medicinal products, Art. 2;
(20)]. For all of these products, periodic safety update reports
(PSURs) containing data on species repartition submitted to
Swissmedic, the Swiss Agency for Therapeutic Products, during
the years 2007 to 2012, were used. As premixes represented
only 28 products from a total of 112 under investigation but
between 57.6% (2015) and 67.8% (2011) of the total sales,
another repartition method had to be used for oral solutions, oral
powders and injectables. This repartition was done according to
biomass repartition as described by Carmo et al. (21). Briefly,
for each product authorized for one or more target species, each
target species was assigned a percentage of kg of the total sales
representing the proportion of its biomass in the total biomass
of the list of authorized species for the product. For the present
study, food producing animal population numbers were obtained
from the Federal Office of Statistics (www.bfs.admin.ch), number
of dogs from the ANIS database (Identitas AG, Bern, www.anis.
ch) and the number of cats from the Swiss Association of pet
food producers (Verband für Heimtiernahrung, Bern, www.vhn.
ch). In analogy with calculations of the population correction
unit (PCU) of ESVAC (12), the number of slaughtered animals
were used for fattening pigs and calves, whereas data for dairy
cows, sows, sheep, goats, horses, dogs, and cats represent live
animals. Throughout the text and in the tables, “pigs” refer to
fattening pigs.
Supplementary Table 1 lists the number of animals and the
weights used for the biomass repartition. The most likely weight
at treatment was sourced from the ESVAC report (12, 22). As
heavy animals with a rather low treatment intensity, like dairy
cows, skew the biomass repartition, we chose to only include
them in the calculation when they were either explicitly listed
as authorized species (“dairy cows”) or, when a withdrawal time
for milk was given in the SPC of the product. For pigs, we did
not include the production stage of piglets or weaners. Using
the number of animals in different production stages presents
some challenges, the most prominent one for pigs being the lack
Number of ACDs =
total quantity of active ingredient sold in one year (mg)
daily dose
(
mg
kg
)
× duration of tratment
(
days
)
× weight at treatment (kg)
Therapeutic intensity in species X =
Number of ACDs in species X
Total number of animals for species X
of available data for the repartition of use between piglets and
e.g., fattening pigs. Only few antimicrobials are primarily used in
piglets or weaners, colistin being such an example. For almost all
other products authorized for pigs, no data are available to stratify
antimicrobial consumption per different age classes using sales
data. Repartition data will only be available once reporting of all
treatments with antimicrobials in Switzerland ismademandatory
at the end of the year 2019. For this reason and because sales
data include the use of antimicrobials by all the age categories of
the species for the years under investigation, we used slaughtered
numbers of pigs as denominator for the therapeutic incidence in
this species. Finally, for injectable products authorized without
indication of the production stage (“bovines” containing dairy
cows and “pigs” representing slaughtered pigs and sows) we used
raw data provided by experts for the study by Carmo et al. (23) to
determine if a use would take place in the particular production
stage under consideration.
Calculation of Animal Course Doses and
Therapeutic Intensity
The Animal Course Dose (ACD) was calculated for each
active pharmaceutical ingredient contained in each product
authorized during the years under investigation. Data were
collected from the authorized summary of product characteristics
(24) and entered into an MS Excel sheet containing: name
of the product, authorization number, list of authorized
species, active ingredient(s), dose and duration. Doses given
in international units were converted to mg using conversion
factors listed in the ESVAC report (12). Whenever the
recommended dose was a range, the highest recommended
dose and longest duration were chosen to reflect the minimal
number of animals potentially treated. Moreover, when different
doses were authorized for different indications, the most
likely indication was chosen. This was the case for products
presenting both a prophylactic or metaphylactic indication
with different doses and duration. ACDs were defined per
kg and the ACD per animal obtained by multiplication with
the likely weight at treatment. To take Swiss specificities into
account, the weight at treatment for pigs was taken from
a previous study by Schnetzer et al. (25) and the weight
for calves based on expert opinion (Prof. M. Kaske, Zurich,
personal communication).
Therapeutic intensity reflects the number of ACDs per
slaughtered animal (pig or calf) in 1 year. For combination
products, the number of ACDs was calculated separately
for each active pharmaceutical ingredient. Therefore, a single
treatment with a combination containing 3 antimicrobials results
in 3 ACDs. ACD and intensity were calculated using the
following equations:
RESULTS
From the year 2011 to 2015, sales of antibiotics for use in food
producing animals decreased by 29.8% (Table 1). In the same
time, the percentage represented by premixes decreased from
67.8 to 57.7%. Therefore, measured in kg, antimicrobials sold in
premixes made the largest part of yearly sales of antimicrobials
for the veterinary medicine. As a consequence, pigs and calves are
the most pertinent species among food producing animals to be
investigated for use and trend detection. In tonnage sold for use
in these species, the decrease in the 5 years under investigation
is comparable: 38.4% in pigs and 30.1% in calves. However,
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TABLE 1 | Sales, biomass and mg per kg biomass for food producing animals as
well as pigs and calves for the years 2011 to 2015.
2011 2012 2013 2014 2015
ALL FOOD PRODUCING ANIMALS
Sales (kg)a 58,942 54,169 50,370 46,147 41,378
% Premixes 67.8 65.7 64.5 61.9 57.7
mg/kg 72 66 62 56 51
PIGS
Sales (kg) 22,475 20,276 18,890 16,458 13,845
mg/kg 121.8 112.5 108.1 92.0 77.4
CALVES
Sales (kg) 21,293 19,299 17,941 16,385 14,886
mg/kg 582.1 537.5 508.3 465.3 449.9
aSales data detailed by antimicrobial classes for the years under investigation
are available under https://www.blv.admin.ch/blv/de/home/tiere/publikationen-und-
forschung/statistiken-berichte-tiere.html.
TABLE 2 | Number of estimated ACDs per pigs or calves, oral and parenteral
application, from 2011 to 2015.
2011 2012 2013 2014 2015
PIGS
Number of ACDs 8,663,191 7,686,268 7,184,114 6,674,046 5,914,349
Number
slaughtered
2,839,106 2,773,726 2,689,576 2,751,721 2,753,256
Intensitya 3.051 2.771 2.671 2.425 2.148
CALVES
Number of ACDs 1,828,599 1,687,942 1,636,930 1,521,050 1,407,450
Number
slaughtered
261,308 256,471 252,118 251,509 236,343
Intensitya 6.998 6.581 6.493 6.048 5.955
aNumber of ACDs per slaughtered animal.
normalizing these numbers to the respective biomass of the
produced (slaughtered) population reveals a much higher use per
kg of biomass for calves (449.9 mg/kg biomass in 2015) than for
pigs (77.4 mg/kg biomass). The difference between both species
even increased from 4.8-fold higher for calves in 2011 to 5.8
in 2015.
Normalizing sales data to either the overall biomass of food
producing animals or to the biomass of a particular species
is a crude estimate of antimicrobials use, not taking dose or
duration into account. We therefore calculated the number of
course doses (ACDs) per product and species. A summary of
the results is presented in Table 2. The total number of ACDs
was approximately 4.5 times higher in pigs and decreased by
31.7% over the years under investigation, whereas the decrease
for calves was 23.0%. Normalization to the number of slaughtered
animals showed a much slower decrease of 14.9% for calves
between 2011 and 2015 compared to 29.6% in pigs. As a result,
the difference between both species grew from 2.3-fold in the year
2011 to 2.8-fold in the final year under investigation.
Not all antibiotics have the same potential impact on
resistance selection and consequences for the treatment of
TABLE 3 | Number of estimated ACDs per animal, antimicrobials administered as
premix or parenterally in pigs and calves for the year 2015, presented by classes
of antimicrobials.
Classes of antimicrobials Pigs Calves
Parenteral Premixes Parenteral Premixes
Sulfonamides 0.050 0.177 0.042 0.632
Penicillins 0.389 0.155 0.477 1.324
Tetracyclines 0.069 0.155 0.057 1.069
Aminoglycosides 0.132 –* 0.210 –*
Amphenicoles 0.054 –* 0.098 –*
Macrolides 0.170 0.145 0.303 0.862
Cephalosporins, 3rd and
4th generation
0.061 –* 0.112 –*
Fluoroquinolones 0.122 –* 0.194 –*
Polymyxins –* 0.189 –* –*
Total 1.088 0.889 1.485 3.942
*No products authorized for the combination of class, species and application route.
both humans and animals. Moreover, different products are
authorized for distinct conditions in pigs or calves. The
repartition of the number of ACDs per class of antimicrobials
was therefore calculated separately for each species for the year
2015. Table 3 presents the repartition by antimicrobial class
for ingredients sold in premixes and as parenteral injections.
In this year, polymyxins (in form of colistin) were the
class with the highest potential numbers of ACDs per pigs,
followed by sulfonamides. In calves, the highest number was
represented by penicillins (mainly sold as aminopenicillins)
followed by tetracyclines. The total number of ACDs per
animal was 4.43 times higher in calves than in pigs. The
same calculation was done for injectable products as these may
contain antimicrobials of the highest priority [HPCIA; (26)]
not available for oral application. For pigs, the highest number
of ACDs per animal in the year 2015 was represented by
macrolides, followed by aminoglycosides and fluoroquinolones.
For calves (amino)penicillins were the class with the highest
number of course doses per animal, followed by macrolides and
aminoglycosides. The total number of potential ACDs per animal
for injectable products in the year 2015 was 1.485 for calves and
1.088 for pigs.
Finally, the evolution of the number of potential ACDs per
animal for HPCIAs is presented in Table 4. For macrolides
used in pigs, a decrease of 22.0% for products sold as
premixes was attenuated by a corresponding increase of
11.8% for injectables. This pattern was even more evident
in calves where a reduction of 27.1% for premixes was
almost completely compensated by an increase of 25.7%
in injectables. With respect to the other two classes of
HPCIAs, sales of products containing fluoroquinolones
remained stable for pigs (−1.5%) and an increase of 6.4% was
observed for the number of potential ACDs per animal in
calves. Courses with cephalosporins of the third and fourth
generations showed a comparable decrease in pigs (−16.4%) and
calves (−15.7%).
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TABLE 4 | Number of estimated ACDs per animal, macrolides, fluoroquinolones
and cephalosporins 3rd and 4th generation, for pigs and calves, by administration
route.
2011 2012 2013 2014 2015
PIGS
Macrolides, premix 0.186 0.199 0.191 0.160 0.145
Macrolides, injections 0.152 0.153 0.171 0.165 0.170
Fluoroquinolones* 0.128 0.115 0.142 0.136 0.126
Cephalosporins* 0.073 0.062 0.064 0.067 0.061
CALVES
Macrolides, premix 1.183 1.087 0.998 0.891 0.862
Macrolides, injections 0.241 0.239 0.291 0.287 0.303
Fluoroquinolones* 0.156 0.145 0.171 0.165 0.166
Cephalosporins* 0.133 0.123 0.121 0.119 0.112
*Only available as injections.
DISCUSSION
This is the first study at national level using the ACD
concept applied to sales of antimicrobials with the objective of
extrapolating the number of potentially treated pigs and calves in
Switzerland. Sales of antimicrobials for the veterinary medicine
are published at national level since 2005. So far, these data
represent the only available source of exhaustive antimicrobial
consumption data at national level. Sales figures may allow for
the recognition of trends, but the lack of information on potency,
dose, duration of treatment and repartition per species strongly
limits their usefulness. The indicator ACD may therefore help to
bridge that gap. Calculation of ACD and repartition of quantities
for products authorized for more than one species would not be
possible without making assumptions, which might influence the
results. The first assumption relates to the weight of the animals.
The standard weight has an impact on both the calculation of the
species repartition and the ACD indicator itself. The impact of
using different weights is a topic beyond the scope of this study
and the impact on calculations has been studied elsewhere (27–
29). In this study we used weights at treatment as close as possible
to the Swiss reality. This should provide the best fitting results,
and also guarantees future reproducibility of the method and
comparison of results, as these weights are likely to be used when
quantifying Swiss antimicrobial consumption both at national
and international level. This approach is comparable to the one
chosen by the ESVAC project.
The method used to stratify antimicrobial consumption by
the production types included in the study has some potential
bias. As it is based on the total biomass of each animal
category, the resulting estimates are highly dependent on the
animal demographics and the animal average weight used. This
might not always be a representative surrogate of the product
repartition by each category. As a reliable repartition is generated
by data collected on actual usage, and such data are currently
not available in Switzerland, we chose an alternative that was
applicable at product level that would deliver reproducible
results over the years and be as accurate as possible. Carmo et
al. (21) have compared three different methods to determine
species repartition of antimicrobials. The longitudinal study
extrapolation method (based on field data) was not applicable
at single product level due to the requirement for minimum,
mode, and maximum starting values. The biomass distribution
was shown to be the method providing the closest results to
the extrapolation based on field data, thereby increasing our
confidence on the pertinence of the approach we applied. The two
main drawbacks of this method are the dependence on defined
average weights and country specific animal demographics.
However, the method, limited by the data available in the
current Swiss context, provides a first insight into antimicrobial
consumption patterns in different species/production types. In
the future, the data collection system IS-ABV (description
available under http://www.aacting.org/matrix/is-abv/?lid=1447)
shall provide further insights into these patterns, as well as a basis
for comparison with the results from themethod and its potential
biases. To make our extrapolations as comparable as possible
with other projects, we used the same standard weights as in the
ESVAC project (12).
It must also be noticed that the denominators of the indicators
presented were based on the number of slaughtered animals
only. The weights used for the calculation of the biomass were
likely weights at treatment as defined in the ESVAC Project (12).
The use of such a calculation might hinder direct comparisons
with other studies and should be taken into consideration
when benchmarking these results. When using the biomass as a
denominator, the result should be interpreted as an indicator for
the amount of active ingredient used per kg of animal produced.
Likewise, the therapeutic intensity indicates the average number
of ACDs per animal produced/slaughtered.
Both a high proportion of heavier animals like cows or,
alternatively, a high treatment intensity in a species of lower
biomass are examples of how animal demographics can bias
the results of the stratification approach based on the biomass.
The repartition across species is mainly influenced by national
production structures. In Switzerland, dairy production is an
important agricultural sector and therefore dairy cows make
a high proportion of the food producing animals’ sector (15).
Cows represented 49% of the total biomass in the year 2015
and this high proportion leads to an underestimation of the
repartition of sales for pigs or calves. This primarily affects
the repartition of aminoglycosides and cephalosporins of the
third generation, which are antimicrobials frequently used in the
treatment of dairy cows. The calculated numbers of ACDs per
animal for these classes presented in Table 4 are, therefore, an
underestimation. Within the same species, biomass repartition
could have been used to estimate the use of antimicrobials
in different production stages of pigs. However, using piglets,
weaners and fattening pigs produced during 1 year introduces
the bias of counting a significant but undefined proportion of the
animals two or three times. As sales data were only available for
one full year, we therefore chose to base our repartition, as well
as the denominator for the treatment intensity, on the number of
pigs slaughtered during the same year. This indicator is used in
this study as a surrogate for all pig production stages.
As the numbers of ACDs represent an extrapolation of usage
data based on sales figures, they follow the latter closely. The
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downward trends in sales is mirrored by the treatment numbers
of both calves and pigs. However, differences become evident as
soon as additional factors like application route are taken into
account. The repartition for pigs in the year 2015 shows that
18% of the active ingredients were used parenterally when based
on quantity, whereas they represented 51% of the treatments
when using ACDs. The main reason for this difference lies in
the potency of the active ingredients: antimicrobials are used
parenterally with a lower dose as there is no loss of active
ingredient compared to the lower bioavailability following oral
application. Another possible reason is the use of more than one
ACD for parenterally applied combination products as 12 of 71
injectable products investigated were combinations of two active
ingredients. Whereas, this approach can be disputed as it shows
a higher number of “treatments,” we think that the use of ACDs
is better suited to test for associations between antimicrobial use
and resistance.
Converting sales of antimicrobials to number of treatments
per animal allows detection of trends that would not be obvious
when only assessing the quantity of active ingredients sold.
Macrolides used to treat calves provide a good example: our
results show a clear shift from the oral application in form
of premixes toward an increase in the use of injectables.
One possible explanation is the increasing availability of
macrolide antibiotics with a long duration of action, e.g.,
tulathromycin, tildipirosin, and gamithromycin. Such active
compounds combine the easy use of a single application with a
long action. Moreover, for parenteral applications, both time to
maximal concentration and maintenance of active levels are not
influenced by the appetite of the animals, therefore guaranteeing
the adequate treatment of sick animals with reduced appetite.
On the negative side, studies about macrolides used in human
medicine convincingly showed a higher level of resistance
selection for longer acting molecules (30).
Our results show a strong difference in the extrapolated usage
of antimicrobials in pigs and calves. This cannot be explained
by a single factor as the administration of antimicrobials is
driven by medical, economic and also psychosocial factors.
Crowding effect, stress during transport of very young, not
yet immunocompetent animals, partially inadequate colostrum
feeding and less than ideal stable climate are among the factors
favoring respiratory problems in calves (31, 32). In the swine
industry, some of the abovementioned factors also exist, but the
structure and management of pig production limits the risks.
Management practices like all-in-all-out including disinfection
between the batches or integrated production from piglet to
finisher can strongly help to reduce antimicrobial usage. In
pigs, there are two main periods at risk for treatment with
antimicrobials: the first at weaning with around 12 kg body
weight and the second at around 25 to 29 kg body weight
(25, 33). In pigs, diarrhea is one of the leading indications
for treatment. This is a very unspecific symptom with many
different causes, including not only bacterial but also dietary or
viral origins. In this context, the availability of vaccines against
both circovirus and Lawsonia intracellularis infections in the
years 2008 to 2010 contributed to the reduction of diarrheal
symptoms, and hence, the rather indiscriminate use of antibiotics
to treat such symptoms. For calves, respiratory diseases are much
more multifactorial and the introduction of various vaccines
(against bovine respiratory syncytial, parainfluenza or corona
virus) seems not to have had the same positive effect as in the
pig industry.
Several factors hinder a proper comparison of our results
with previously published data. To the best of our knowledge,
this is the first time that the ACD indicator is used at national
level in Switzerland. As a matter of fact, its use is not currently
widespread in other countries, with the exception of France
where it was developed. However, the comparison with French
data is difficult. No publication presents the French antimicrobial
consumption using ACDs per animal and year as an indicator.
The French indicator for exposure to antimicrobials is ALEA
[Animal Level of Exposure to Antimicrobials; (16)]. It is obtained
by dividing the effectively treated biomass by the total biomass
of the same species. The global ALEA calculated for the year
2015 in France was 0.488 and represented a decrease of 20.1%
compared to 2011. Another difficulty is the use of different
production categories and standard weights at treatment. For
pigs, the French system uses weights up to 350 kg for a specific
category of sows and the average for the pig population is set
at 105 kg. This is 3.62 times higher than the standard weight
at treatment of 29 kg identified in previous Swiss studies and
used here. The differences in the standard weights at treatment
also explain the discrepancies in the antimicrobial consumption
for France published, for the same year, in the ESVAC report
(107 mg/PCU) and in the ANSES report (47 mg/kg). Due to the
differences in weight and in the categories, and the difficulties
in making assumptions and extrapolations, we decided not the
compare our figures to the French ones.
Our data can only be compared with countries where calves
are reared for the production of veal meat. Besides France
and Belgium (for which country we could not find adequate
data for comparison), this production system also exists in The
Netherlands. The available report for the year 2015 (34) uses
indicators differing from the ones in the present study but still
shows a higher treatment intensity in calves compared to pigs.
This is in line with the present study, where the antimicrobial use
was 2.77-fold higher in calves than in pigs.
Both examples clearly illustrate the need to harmonize
methodologies at international level in order to discuss data
collected in different countries. Such discussions currently take
place within the AACTNG network (www.aacting.org).
CONCLUSION
This first study of the number of treatments of pigs and
calves extrapolated from yearly sales shows both similarities
and differences between the two species under consideration.
Whereas, the sales by species and the number of extrapolated
treatments both decreased in a similar way, the difference in
the number of treatments per animal between pigs and calves
differed over the years under investigation. Given that the applied
method is based on the extrapolation of sales figures, a similar
decrease at species level was to be expected. However, the use of
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course doses allows to further investigate trends in the patterns
of antimicrobial treatments. In our study, this was very clear
for the class of macrolides, for which the decreases in oral use
were partly (pigs) or completely (calves) compensated by the
application of long acting injectables. We, therefore, recommend
the use of extrapolated treatment numbers when no exhaustive
collection of usage data is in place. The concept of ACDs can also
complement the collection of antimicrobial consumption data at
species level allowing for their validation using sales data.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
manuscript/Supplementary Files.
AUTHOR CONTRIBUTIONS
RS did all the calculations presented in this work. LC
helped with the repartition of sales between species,
expert advice and biomass distribution. Raw sales data
and advice regarding their use was provided by DH.
The study was designed by CM and supervised by
KE and HN.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fvets.
2019.00318/full#supplementary-material
REFERENCES
1. Swann MM. Joint Committee on the Use of Antibiotics in Animal Husbandry
and Veterinary Medicine. London: H.M.S.O (1969).
2. WHO, World Health Organization. The Medical Impact of the Use of
Antimicrobials in Food Animals. Geneva: World Health Organization (1997).
3. FSVO, Federal Food Safety and Veterinary Office. ARCH-VET 2017: Bericht
über den Vertrieb von Antibiotika in der Veterinärmedizin in der Schweiz
[ARCH-VET 2017: Report on Sales of Antibiotics for Veterinary use in
Switzerland]. (2018). Available online at: https://www.blv.admin.ch/dam/blv/
de/dokumente/tiere/tierkrankheiten-und-arzneimittel/tierarzneimittel/arch-
vet-bericht-2017.pdf.download.pdf/ARCH-Vet_Sales_2017%20D.pdf
4. DANMAP. Use of Antimicrobial Agents and Occurrence of Antimicrobial
Resistance in Bacteria From Food Animals, Food and Humans in Denmark.
(2017). Available online at: https://www.danmap.org/-/media/arkiv/projekt-
sites/danmap/danmap-reports/danmap-2017/danmap2017.pdf?la=en
5. EMA, European Medicines Agency, European Surveillance of Veterinary
Antimicrobial Consumption. Sales of veterinary antimicrobial agents in
30 European countries in 2016: Eighth ESVAC report. (2018). Available
online at: https://www.ema.europa.eu/documents/report/sales-veterinary-
antimicrobial-agents-30-european-countries-2016-trends-2010-2016-
eighth-esvac_en.pdf
6. WHO, World Health Organization. Joint FAO/OIE/WHO Expert Workshop
on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific
assessment, Geneva. (2003). Available online at: http://whqlibdoc.who.int/hq/
2004/WHO_CDS_CPE_ZFK_2004.7.pdf
7. Van Gompel L, Luiken REC, Sarrazin S, Munk P, Knudsen B E, Hansen RB, et
al. The antimicrobial resistome in relation to antimicrobial use and biosecurity
in pig farming, a metagenome-wide association study in nine European
countries. J Antimicrob Chemother. (2019) 74:865–76. doi: 10.1093/jac/dky518
8. Raasch S, Postma M, Dewulf J, Stärk KDC, Beilage EG. Association between
antimicrobial usage, biosecurity measures as well as farm performance
in German farrow-to-finish farms. Porcine Health Manag. (2013) 4:30.
doi: 10.1186/s40813-018-0106-5
9. Holstege MMC, de Bont-Smolenaars AJG, Santman-Berends IMGA, van der
Linde-Witteveen GM, van Schaik G, Velthuis AGJ, et al. Factors associated
with high antimicrobial use in young calves on Dutch dairy farms: a case-
control study. J Dairy Sci. (2018) 101:9259–65. doi: 10.3168/jds.2017-14252
10. Nicholls T, Acar J, Anthony F, et al. Antimicrobial resistance: monitoring the
quantities of antimicrobials used in animal husbandry. Rev Off Int Epizoot.
(2001) 20:841–7. doi: 10.20506/rst.20.3.1317
11. MARAN. Monitoring of Antimicrobial Resistance and Antibiotic Usage in
Animals in the Netherlands in 2017. (2016). Available online at: https://www.
wur.nl/upload_mm/7/b/0/5e568649-c674-420e-a2ca-acc8ca56f016_Maran
%202018.pdf
12. EMA, European Medicines Agency. European Surveillance of Veterinary
Antimicrobial Consumption. Trends in the Sales of Veterinary Antimicrobial
Agents in Nine European Countries (2005-2009). (2011). Available online
at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/
09/WC500112309.pdf
13. OIE, Annual report on antimicrobial agents intended for use in animals. Better
Understanding of the Global Situation. Third Report. World Organisation
for Animal Health (OIE). (2018). Available online at: http://www.oie.int/
fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/Annual_
Report_AMR_3.pdf
14. Health Canada. Canadian Antimicrobial Resistance Surveillance System.
Report. Public Health Agency of Canada, Ottawa. (2018). Available online
at: https://www.canada.ca/content/dam/phac-aspc/documents/services/
publications/drugs-health-products/canadian-antimicrobial-resistance-
surveillance-system-2017-report-executive-summary/CARSS-Report-2017-
En.pdf
15. Grave K, Torren-Edo J, Mackay D. Comparison of the sales of veterinary
antibacterial agents between 10 European countries. J Antimicrob Chemother.
(2010) 65:2037–40. doi: 10.1093/jac/dkq247
16. ANSES. Suivi des ventes de médicaments vétérinaires contenant des
antibiotiques en France en 2015. ANSES - Agence nationale du médicament
vétérinaire, Fougères. (2016). Available online at: https://www.anses.fr/fr/
system/files/ANMV-Ra-Antibiotiques2015.pdf
17. EMA, European Medicines Agency. European Surveillance of Veterinary
Antimicrobial Consumption. EMA/224954/2016: Defined Daily Doses for
Animals (DDDvet) and Defined Course Doses for Animals (DCDvet).
(2011). Availble online at: https://www.ema.europa.eu/documents/other/
defined-daily-doses-animals-dddvet-defined-course-doses-animals-dcdvet-
european-surveillance_en.pdf
18. TAMV. Verordnung über die Tierarzneimittel [Ordinance on Veterinary
Medicinal Products], SR 812.212.27, Version from January 1st. (2019).
Available online at: https://www.admin.ch/opc/de/classified-compilation/
20030705/index.html
19. WHOCC. ATCvet Index 2019. WHO Collaborating Centre for Drug Statistics
Methodology Norwegian Institute of Public Health, Oslo. (2019). Availble
online at: https://www.whocc.no/atcvet/atcvet_index/
20. AMBV.Verordnung über die Bewilligungen imArzneimittelbereich [Ordinance
on authorization for medicinal products], SR 812.212.1, Version from January
1st. (2019). Available online at: https://www.admin.ch/opc/de/classified-
compilation/20180857/index.html
21. Carmo LP, Schüpbach-Regula G, Müntener CR, Chevance A, Moulin G,
Magouras I. Approaches for quantifying antimicrobial consumption per
animal species based on national sales data: a Swiss example, 2006 to 2013.
Euro Surveill. (2017) 22:30458. doi: 10.2807/1560-7917.ES.2017.22.6.30458
22. Montforts M. Validation of the exposure assessment for
veterinary medicinal products. J Sci Tot Env. (2006) 358:121–36.
doi: 10.1016/j.scitotenv.2005.04.008
23. Carmo LP, Bouzalas I, Nielsen LR, et al. Expert opinion on
livestock antimicrobial usage indications and patterns in Denmark,
Portugal and Switzerland. Veterinary Record Open. (2018) 5:e000288.
doi: 10.1136/vetreco-2018-000288
Frontiers in Veterinary Science | www.frontiersin.org 7 September 2019 | Volume 6 | Article 318
Stebler et al. Extrapolating Sales to Number of Treatments
24. IVPT. Institut für Veterinärpharmakologie und -toxikologie. Swiss Veterinary
Drug Compendium. (2017). Available online at: https://www.vetpharm.uzh.
ch/perldocs/index_t.htm
25. Schnetzer P, Brügger M, Naegeli H, Müntener CR. Therapieintensität
beim Einsatz von Fütterungsarzneimitteln bei Schweinen [Calculation of
therapeutic intensity for pigs treated using medicated feed]. Schweiz Arch
Tierheilk. (2017) 159:381–6. doi: 10.17236/sat00121
26. WHO, World Health Organization. Critically important antimicrobials for
human medicine – 5th rev. (2017). Available online at: http://apps.who.int/
iris/bitstream/10665/255027/1/9789241512220-eng.pdf
27. Pardon B, Catry B, Dewulf J, Persoons D, Hostens M, De Bleecker K, et
al. Prospective study on quantitative and qualitative antimicrobial and anti-
inflammatory drug use in white veal calves. J Antimicrob Chemother. (2012)
67:1027–38. doi: 10.1093/jac/dkr570
28. Bondt N, Jensen VF, Puister-Jansen LF, van Geijlswijk IM. Comparing
antimicrobial exposure based on sales data. Prev Vet Med. (2013) 108:10–20.
doi: 10.1016/j.prevetmed.2012.07.009
29. Filippitzi ME, Callens B, Pardon B, Persoons D, Dewulf J. Antimicrobial use in
pigs, broilers and veal calves in Belgium. Vlaams diergeneeskundig tijdschrift.
(2014) 83:215–24
30. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H.
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage
of macrolide-resistant streptococci in healthy volunteers: a randomised,
double-blind, placebo-controlled study. Lancet. (2007) 369:482–90.
doi: 10.1016/S0140-6736(07)60235-9
31. Bähler C, Steiner A, Luginbühl A, Ewy A, Posthaus H, Strabel D, et al.
Risk factors for death and unwanted early slaughter in Swiss veal calves
kept at a specific animal welfare standard. Res Vet Sci. (2012) 92:162–8.
doi: 10.1016/j.rvsc.2010.10.009
32. Lava M, Schüpbach-Regula G, Steiner A, Meylan M. Antimicrobial
drug use and risk factors associated with treatment incidence and
mortality in Swiss veal calves reared under improved welfare conditions.
Prev Vet Med. (2016) 126:121–30. doi: 10.1016/j.prevetmed.2016.
02.002
33. Müntener CR, Stebler R, Horisberger U, Althaus RF, Gassner B. Berechnung
der therapieintensität bei ferkeln und mastschweinen beim einsatz von
antibiotika in fütterungsarzneimitteln. Schweiz Arch Tierheilk. (2013)
155:365–72. doi: 10.1024/0036-7281/a000472
34. MARAN. Monitoring of Antimicrobial Resistance and Antibiotic Usage in
Animals in the Netherlands in 2015. (2016). Available online at: https://www.
wur.nl/upload_mm/0/b/c/433ca2d5-c97f-4aa1-ad34-a45ad522df95_92416_
008804_NethmapMaran2016+TG2.pdf
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Stebler, Carmo, Heim, Naegeli, Eichler and Muentener. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Veterinary Science | www.frontiersin.org 8 September 2019 | Volume 6 | Article 318
